Your session is about to expire
← Back to Search
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up predose and 1, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 168, and 192 hours post dose
Awards & highlights
Summary
This trial involves people with severe liver problems taking a single tablet of EQ143. The study will monitor the drug and its breakdown product in their blood, check how they bind to proteins, and ensure it is safe.
Eligible Conditions
- Liver Damage
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ predose and 1, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 168, and 192 hours post dose
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~predose and 1, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 168, and 192 hours post dose
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
PK Parameter: AUC0-t of EQ143
PK Parameter: AUC0-t of metabolite, HAS719
PK Parameter: AUCinf of EQ143
+4 moreSecondary study objectives
Number of Participants with Adverse Event
Trial Design
1Treatment groups
Experimental Treatment
Group I: AumolertinibExperimental Treatment1 Intervention
single dose oral 55mg of aumolertinib
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
aumolertinib
2021
Completed Phase 1
~60
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
EQRx, Inc.Lead Sponsor
3 Previous Clinical Trials
145 Total Patients Enrolled
EQRx International, Inc.Lead Sponsor
3 Previous Clinical Trials
8 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger